Novacta Biosystems

About:

Novacta Biosystems develops and markets drugs for the treatment of bacterial infections, especially those caused by drug resistant bacteria.

Website: http://www.novactabio.com

Top Investors: Wellcome Trust, UK Innovation & Science Seed Fund, Oxford Technology Management, Iceni Seedcorn Fund, Esperante Ventures

Description:

Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.